when allowed to drink to thirst, mitigating the need for desmopressin. Temozolomide was not restarted and the symptoms of polyuria and polydipsia resolved and did not recur. Upon review, the tumor did not involve the pituitary or hypothalamus. Additionally, these areas were not involved in the irradiation field. CDI is a rare but clinically significant side effect of temozolomide, reported in adults. Given this is the first report of CDI secondary to temozolomide in a pediatric patient, we speculate that this is likely under-recognized in children. Prompt recognition and treatment is necessary to prevent severe sequelae of hypernatremia.

OTHR-12. ANEURYSMAL BONE CYST RESEMBLING A POSTERIOR FOSSA TUMOR

Luis Angel Arredondo Navarro[1,2],
Regina Malinali Navarro Martin Del Campo[1,2],
Gutierrez Oliva Lorelay Livier[1], Valeria Estefania Aguilar Mercado[1],
Juan Luis and Soto Mancilla[1]; [1]Hospital Civil de Guadalaja, Guadalajara, Jalisco, Mexico, [2]GAP-NO, International, Mexico

We presented the case of a 6-year-old boy who was seen in the emergency room because of signs of intracranial hypertension and left cerebellar syndrome. The CT scan revealed a heterogeneous lesion within the left hemisphere displacing the fourth ventricle and eroding the occipital bone. The MRI showed the same heterogeneous lesion majorly cystic, involving the bone and displacing the left cerebellar hemisphere. A minor hydrocephalus was evident in both studies. A suboccipital craniectomy was done and a cystic epidural tumor remodeling and eroding the bone was noted. The histopathological diagnosis corresponded to an aneurysmal bone cyst. Aneurysmal bone cyst is a rare benign tumor accounting for 3–6 % of tumors of the cranial base. We discuss the unusual location of the lesion.

OTHR-14. DIENCEPHALIC SYNDROME SECONDARY TO PITUITARY STALK THICKENING

Carlos Almeida Jr, Bruna Minniti Mançano, Gilda D'Agostino Eugui, Marcus Matsushita, Gabrielle Alvarenga, and Lucas Dias Lourenço; Barretos´s Children and Young Adults Cancer Hospital, Barretos, Sao Paulo, Brazil

BACKGROUND: Diencephalic syndrome (DS) is a rare condition associated with neoplastic lesions of the sellar-suprasellar region, whose pathophysiological mechanisms are still unclear. DS occurs in <10% of hypothalamic gliomas and has also been described in suprasellar germinomas, craniopharyngiomas, epidermoid cysts, rarely with non-suprasellar lesions such as brainstem gliomas. DS has not been associated with isolated pituitary stalk thickening. Isolated pituitary stalk thickening (IPST) presents a diagnostic challenge, ranging from benign (craniopharyngioma) to malignant lesions (germinoma, metastasis, histiocytoses of the Langerhans group). The coexistence of diabetes insipidus (DI) with anterior pituitary dysfunction and IPST implies more risk to harbor neoplasia. CASE REPORT: A 6-year old girl presented with DI and inadequate weight gain (despite regular caloric intake) and preservation of linear growth. Neurological examination showed no abnormalities. However, physical examination revealed a malnourished patient (both weight-for-age value and body-mass-index below the third percentile). Blood tests and negative IgA anti-endomysial antibodies excluded malabsorption as a cause of her malnutrition; endocrine work-up excluded thyroid dysfunction, growth hormone deficiency, and adrenal insufficiency. Magnetic resonance imaging (MRI) showed thickening of the pituitary stalk with a transverse diameter of 7 mm. The patient underwent a biopsy through a supraorbital eyebrow approach. Histopathological examination revealed lymphocytic hypophysitis, with tissue markers all negative for germinoma. The girl is currently under follow up with serial MRI every three months. CONCLUSION: DS should be considered as a differential diagnosis in any child with failure to thrive, and imaging studies should be performed even if there are no additional neurological symptoms.

OTHR-16. CONCURRENT USE OF APREPITANT AND IFOSFAMIDE IN PEDIATRIC CANCER PATIENTS

Shelby Winzent, Nathan Dahl, Molly Hemenway, Rachel Lovria, and Kathleen Dorris; Univ of CO, SOM, Children's Hospital Colorado, Aurora, CO, USA

BACKGROUND: Aprepitant, a selective neurokinin-1 receptor antagonist, is commonly used for prevention of chemotherapy-induced nausea and vomiting. Its use with ifosfamide is controversial due to the putative risk of potentiating neurotoxicity via inhibition of cytochrome P450 3A4 (CYP3A4). The current literature examining this interaction is inconclusive, and little data exists in pediatrics. We seek to describe a single-institution experience with concurrent aprepitant and ifosfamide administration. METHODS: A retrospective review of patients treated with ifosfamide and aprepitant from 2009–2018 was conducted. Data collected included demographics, tumor type, number of days of concurrent therapy, dosing, and documented of neurotoxicity. RESULTS: Twenty patients aged 7–21 years (median 17 years) were identified. Diagnoses included thirteen sarcomas and seven CNS tumors (6 germ cell tumors; 1 intracranial sarcoma). Five patients received high dose ifosfamide (>2,000mg/m^2/day). The number of concurrent ifosfamide and aprepitant doses ranged from 2–18 (median, 8.5). Only one patient (5%) developed ifosfamide-induced neurotoxicity: a 7-year-old female with a nongerminomatous germ cell tumor who presented with seizures and somnolence. She received methylene blue and returned to her neurologic baseline. She completed her ifosfamide course without incident. She was the only patient to require weight-based aprepitant dosing and to receive the liquid formulation. CONCLUSIONS: Aprepitant should be used with caution when administered concurrently with ifosfamide due to the risk of neurotoxicity. However, the incidence of neurotoxicity in this retrospective pediatric cohort was low. This interaction may be more significant in younger patients due to age-related differences in hepatic metabolism, but further study is required.

PATHOLOGY AND MOLECULAR DIAGNOSIS

PATH-01. MOLECULAR PROFILING OF PAEDIATRIC CENTRAL NERVOUS SYSTEM TUMOURS IN AUSTRALASIA – AN UPDATE ON THE AIM BRAIN AND MNP2.0 PROJECTS

Elizabeth Algar[1,2], White Christine[1], Kathryn Kinross[3], Molly Buntine[1], David Jones[4], Stefan Pfister[4], Robyn Strong[3], Nicholas Gottardo[5,6], and Jordan Hansford[7,8]; [1]Hudson Institute of Medical Research, Melbourne, Victoria, Australia, [2]Monash University, Melbourne, Victoria, Australia, [3]Australian and New Zealand Children's Oncology Group, Melbourne, Victoria, Australia, [4]Hopp Children's Cancer Center, Heidelberg, Germany, [5]Perth Children's Hospital, Perth, Western Australia, Australia, [6]Telethon Kids Institute, Perth, Western Australia, Australia, [7]Royal Children's Hospital, Melbourne, Victoria, Australia, [8]University of Melbourne, Melbourne, Victoria, Australia

The Access to Innovative Molecular Profiling for Paediatric Brain Cancers (AIM BRAIN) project is a trial testing the feasibility of clinical implementation of diagnostic methylation and molecular profiling for central nervous system (CNS) tumours in Australia and New Zealand. AIM BRAIN builds on an existing study, MNP2.0, and allows cross-validation of results derived from identical samples in separate laboratories in Melbourne, Australia, and DKFZ, Heidelberg, Germany. Parallel methylation profiling (Illumina 850K EPIC array) from co-enrolled cases has revealed excellent concordance between laboratories with 50/51 cases (98%) yielding identical classification using the DKFZ Molecular Neuropathology 2.0 Classifier v11b4. 77/91 (85%) of AIM BRAIN cases classified concordantly by methylation array when compared to their diagnostic histopathology. Of these 77 cases, 16 had classifications below a threshold of 0.90, however still classified correctly. In 14 discordant cases either the histopathology was not well defined, not represented on the classifier, or a very low classification score was obtained. Molecular profiling through MNP2.0 identified 49/167 (29.3%) tumours with gene fusions including BRAF-KIAA1549 (n=29), *RELA-C1orf95* (n=5) and 15 rare or novel fusions. BRAF-KIAA1549 was almost exclusively associated with pilocytic astrocytoma (28/29) and RELA-*C1orf95* with ependymoma. Six pathogenic germline mutations were identified in *TP53* (n=2), *BRCA1*, *NF1*, *LZTR1* and *ATM*. The incidence of germline predisposition was low (4%) and sex biased towards females (5F:1M), (p<0.08). Our findings confirm methylation profiling as a robust platform for classifying CNS tumours with potential to reveal new CNS tumour entities when combined with molecular profiling.

PATH-03. HIGH-GRADE NEUROEPITHELIAL TUMOR SHOWING BCOR IMMUNOPOSITIVITY WITHOUT EXON 15 INTERNAL TANDEM DUPLICATIONS IN A FIVE-YEAR-OLD BOY: A CASE REPORT

Shogo Wakita[1], Tomoo Matsutani[1], Yosuke Watanabe[1], Seiichiro Hirono[1], Yoshinori Higuchi[1], Yasuo Iwadate[1], Zyunichiro Ikeda[2], and Hideaki Yokoo[3]; [1]Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, Japan, [2]Department of Diagnostic Pathology, Chiba University Graduate School of Medicine, Chiba, Japan, [3]Department of Pathology, Gunma University Graduate School of Medicine, Gunma, Japan

Recent DNA methylation profiling clarified several rare entities of pediatric CNS tumors from institutionally-diagnosed primitive neuroectodermal tumors (PNETs). One of which is CNS high-grade neuroepithelial tumor with *BCOR* alteration (CNS HGNET-*BCOR*), and it carries in-frame internal tandem duplications (ITD) of the *BCL6 corepressor (BCOR)* in exon 15. In the report, we describe a case of immunohistologically-diagnosed CNS HGNET-*BCOR*, which lacks exon 15 ITD of *BCOR*. A five-year-old boy visited a local hospital complaining uncontrolled vomiting for two months,